Meiji Holdings Co (2269) AI Stock Analysis

• Market Cap: ¥821.35B
• Dividend Yield: 3.46%
• Average Volume (3M): 1.53M
• Price to Earnings (P/E): 17.3
• Beta (1Y): 0.02
• Revenue Growth: 2.45%
• EPS Growth: -9.06%
• Country: JP
• Employees: 17,270
• Sector: Consumer Defensive
• Sector Strength: 42
• Industry: Packaged Foods
• EPS (TTM): 37.27
• Shares Outstanding: 282,200,000
• 10 Day Avg. Volume: 1,604,540
• 30 Day Avg. Volume: 1,527,050
• PEG Ratio: 7.15
• Price to Book (P/B): 1.19
• Price to Sales (P/S): 0.77
• P/FCF Ratio: 54.83
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ¥3,299.65
• Price Target Upside: 8.79% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1
• EPS Forecast (FY): 202.16
• Revenue Forecast (FY): ¥1.18T

• Rating: 64 Neutral
• Price Target: ¥3,208.00 ▲(5.77% Upside)

Meiji Holdings Co's overall stock score is driven by its financial stability and attractive valuation. However, the bearish technical indicators and declining revenue growth are concerns. The company's strong equity position and dividend yield provide some support against market fluctuations.

Meiji Holdings Co Business Overview & Revenue Model

Company Description

Meiji Holdings Co., Ltd., through its subsidiaries, manufactures and sells dairy products, confectioneries, nutritional products, and pharmaceuticals in Japan and internationally. The company operates through two segments, Food and Pharmaceutical. It provides yogurt, drinking milk, beverages, cheese, butter and margarine, cream, ice cream, frozen foods, chocolates, gummy products, chewing gums, candies, sports nutrition products, infant and eternal formula, beauty supplements, OTC drugs, livestock products, and sugar, as well as transportation and distribution services. The company also provides drugs for infectious diseases and central nervous system disorders, as well as generic drugs; agricultural and livestock chemicals; human and veterinary vaccines, and blood plasma products; and veterinary drugs for livestock and fisheries comprising antimicrobial injection, oral administration, antipyretic, analgesic, anti-inflammatory, hemostatic, and breeding agents, disinfectants, insecticides, anthelmintics, metabolites, feed additives, and mixed feed; and companion animals, including anesthetics and painkillers, anti-parasitic and gastrointestinal drugs, anti-bacterial agents, antiplasmin agents, vitamin E preparations, and dietary supplements. Meiji Holdings Co., Ltd. was founded in 1916 and is headquartered in Tokyo, Japan.

How the Company Makes Money

Meiji Holdings generates revenue primarily through the sale of its food and pharmaceutical products. The Food Division is a key revenue driver, offering various dairy products such as milk, yogurt, and cheese, alongside confectionery items like chocolate and snacks. The Pharmaceuticals Division contributes significantly to earnings through the development and sale of prescription medications and vaccines. Additionally, Meiji engages in strategic partnerships with healthcare providers and distributors, enhancing its market reach and sales capabilities. The company also invests in research and development to innovate and expand its product offerings, thereby attracting a broader customer base and increasing its revenue potential.

Meiji Holdings Co Financial Statement Overview

Summary

Meiji Holdings Co shows solid revenue growth and strong operational margins. The balance sheet reflects financial stability with low leverage and high equity. However, the reduction in free cash flow indicates potential challenges in cash management. Overall, the company demonstrates strength in core operations but should focus on optimizing cash flow and profitability.

Income Statement

Meiji Holdings Co has shown consistent revenue growth, with a 4.39% increase from 2024 to 2025. Gross profit margin in 2025 is solid at 29.39%, reflecting efficient cost management. However, net profit margin is somewhat lower at 4.40%, indicating higher expenses or interest costs impacting profitability. The EBIT margin is healthy at 7.34%, and the EBITDA margin is robust at 11.94%, showcasing operational efficiency.

Balance Sheet

The company maintains a strong equity position, with a debt-to-equity ratio of 0.06, indicating low leverage. The equity ratio is high at 63.18%, suggesting financial stability. Return on equity (ROE) is moderate at 6.79%, which may indicate room for improving profitability relative to equity.

Cash Flow

Operating cash flow to net income ratio is 1.36, indicating strong cash generation relative to reported earnings. However, there is a significant decrease in free cash flow from 2024 to 2025, leading to a negative free cash flow growth rate of -70.33%. The free cash flow to net income ratio stands at 0.32, suggesting a need for improved cash conservation strategies.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.15T	1.15T	1.11T	1.06T	1.01T	1.19T
Gross Profit	337.10B	339.10B	336.88B	306.80B	323.25B	449.63B
EBITDA	134.42B	137.84B	143.20B	149.46B	179.07B	152.23B
Net Income	46.95B	50.80B	50.67B	69.42B	87.50B	65.66B
Balance Sheet
Total Assets	1.20T	1.18T	1.21T	1.14T	1.12T	1.07T
Cash, Cash Equivalents and Short-Term Investments	86.21B	78.19B	106.86B	63.52B	67.41B	40.33B
Total Debt	89.77B	47.80B	49.93B	64.37B	81.27B	101.78B
Total Liabilities	416.07B	392.69B	417.50B	384.91B	404.44B	407.64B
Stockholders Equity	742.02B	748.29B	746.53B	711.91B	673.34B	621.43B
Cash Flow
Free Cash Flow	31.17B	16.18B	54.54B	12.84B	34.36B	55.78B
Operating Cash Flow	83.27B	68.98B	107.98B	85.01B	127.53B	123.68B
Investing Cash Flow	-64.82B	-40.64B	-24.60B	-36.79B	-27.61B	-93.11B
Financing Cash Flow	-28.05B	-61.67B	-43.77B	-54.73B	-77.00B	-28.29B

Meiji Holdings Co Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 3033.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:2269, the sentiment is Negative. The current price of 3033 is above the 20-day moving average (MA) of 3003.77, below the 50-day MA of 3047.55, and below the 200-day MA of 3104.89, indicating a bearish trend. The MACD of -17.20 indicates Positive momentum. The RSI at 45.13 is Neutral, neither overbought nor oversold. The STOCH value of 24.53 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:2269.

Meiji Holdings Co Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2875	76 Outperform	$1.04T	15.72	13.26%	1.95%	3.64%	5.31%
2871	72 Outperform	¥462.24B	19.29	9.74%	2.39%	2.10%	-7.06%
2002	70 Outperform	¥499.16B	20.90	―	3.39%	-0.88%	-25.64%
2897	68 Neutral	$817.87B	16.30	10.68%	2.52%	2.27%	-7.76%
2269	64 Neutral	¥821.35B	17.28	6.40%	3.46%	2.45%	-9.06%
Sector *	62 Neutral	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%
2282	59 Neutral	¥560.15B	17.71	6.04%	2.38%	5.10%	-13.09%

Meiji Holdings Co Corporate Events

Meiji Holdings Completes Treasury Stock Disposal for Incentive Plan

Meiji Holdings Co., Ltd. has completed the payment for the disposal of its treasury stock under a restricted stock incentive plan for managerial employees. This disposal, initially resolved in July 2025, saw a slight change in the number of shares due to the forfeiture of rights by one employee. The company assures that there will be no impact on its financial forecast for the fiscal year ending March 31, 2026.

The most recent analyst rating on (JP:2269) stock is a Buy with a Yen3411.00 price target. To see the full list of analyst forecasts on Meiji Holdings Co stock, see the JP:2269 Stock Forecast page.

Meiji Holdings Reports Decline in Q1 Profits

Meiji Holdings Co., Ltd. is a leading Japanese company operating in the food and pharmaceutical sectors, known for its diverse range of products including dairy, chocolate, nutrition, and pharmaceuticals. In its latest earnings report for the first quarter of the fiscal year ending March 31, 2026, Meiji Holdings reported a decline in net sales and profits compared to the previous year. Net sales decreased by 1.8% to JPY 273.569 billion, while operating profit and ordinary profit fell by 13.4% and 13.3% respectively. Profit attributable to owners of the parent dropped significantly by 27.6% to JPY 10.095 billion.

Meiji Holdings Reports First Quarter Decline but Projects Full-Year Growth

Meiji Holdings Co., Ltd. reported a decline in its financial performance for the first quarter of the fiscal year ending March 31, 2026, with net sales decreasing by 1.8% and a significant drop in profit attributable to owners of the parent by 27.6% compared to the previous year. Despite the current downturn, the company forecasts a 3.5% increase in net sales for the full fiscal year, indicating a potential recovery and growth, which may impact its market positioning and stakeholder confidence.

The most recent analyst rating on (JP:2269) stock is a Hold with a Yen3500.00 price target. To see the full list of analyst forecasts on Meiji Holdings Co stock, see the JP:2269 Stock Forecast page.

Meiji Holdings Completes Treasury Stock Disposal for Director Compensation

Meiji Holdings Co., Ltd. has completed the payment for the disposal of treasury stock intended as Restricted Stock Compensation for its directors and executive officers. This move involves the disposal of 197,022 common shares at a value of JPY 3,186 per share, totaling JPY 627,712,092, and is part of the company’s strategy to incentivize its leadership team, potentially impacting its governance and operational alignment.

The most recent analyst rating on (JP:2269) stock is a Hold with a Yen3500.00 price target. To see the full list of analyst forecasts on Meiji Holdings Co stock, see the JP:2269 Stock Forecast page.